Back to discover
Disease
Thymoma
Late-stage therapeutic developmentEmerging research
2
Publications
21
Clinical trials
2
Related conditions
2023
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Genomic characterization of thymic epithelial tumors in a real-world dataset.
Research2023-09-12ESMO open
Research2023-09-09Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 3 clinical trials expected to report results, the earliest in Q1 2027.
Upcoming Milestones
- Q1 2027A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
- Q2 2027A Phase 1/2, Open-Label, Target-Selected Study of Allogeneic CAR-NK Cells Directed to CD30, CD5, or Mesothelin in Patients With Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
- Q4 2027A Phase II, Open-Label Trial of PT-112 in Subjects With Thymoma and Thymic Carcinoma
Major developments
Upcoming trial readoutHigh impact
Results expected Q4 20272026-06-25
Upcoming trial readoutHigh impact
Results expected Q1 20272026-06-25
Clinical MilestonesViewHide
Results expected
- 2026-06-25A Phase II, Open-Label Trial of PT-112 in Subjects With Thymoma and Thymic CarcinomaResults expected Q4 2027
- 2026-06-25A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based ChemotherapyResults expected Q1 2027
- 2026-05-20A Phase 1/2, Open-Label, Target-Selected Study of Allogeneic CAR-NK Cells Directed to CD30, CD5, or Mesothelin in Patients With Relapsed/Refractory B2 Thymoma or Thymic CarcinomaResults expected Q2 2027
Recently completed
Other updates
- 2030-07-01The Study of Extended Thymectomy and Pleural Reductive Surgery (PRS) With Povidone-iodine Pleural Lavage in Patients With Stage IVA Thymic MalignanciesWithdrawn
- 2026-12-01A Randomized Phase III Study of Adjuvant Radiotherapy Versus Adjuvant Radiochemotherapy in Patients With Incomplete ResectionThymoma or Thymic CarcinomaWithdrawn
Activity timeline7
- 2030-07-01ClinicalThe Study of Extended Thymectomy and Pleural Reductive Surgery (PRS) With Povidone-iodine Pleural Lavage in Patients With Stage IVA Thymic MalignanciesWithdrawn
- 2026-12-01ClinicalA Randomized Phase III Study of Adjuvant Radiotherapy Versus Adjuvant Radiochemotherapy in Patients With Incomplete ResectionThymoma or Thymic CarcinomaWithdrawn
- 2026-07-31ClinicalA Phase II, Open-Label Trial of Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic CarcinomaPrimary completion
- 2026-06-25ClinicalA Phase II, Open-Label Trial of PT-112 in Subjects With Thymoma and Thymic CarcinomaResults expected Q4 2027
- 2026-06-25ClinicalA Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based ChemotherapyResults expected Q1 2027
- 2026-05-20ClinicalA Phase 1/2, Open-Label, Target-Selected Study of Allogeneic CAR-NK Cells Directed to CD30, CD5, or Mesothelin in Patients With Relapsed/Refractory B2 Thymoma or Thymic CarcinomaResults expected Q2 2027
- 2026-05-01ClinicalA Prospective, Randomized, Controlled Phase Ⅱ Clinical Trial of Neoadjuvant Radiotherapy for Locally Advanced Unresectable ThymomaPrimary completion
Clinical trials
The current development programme across all trial phases.
Clinical programme
21
6
1
6
Late-stage studies
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Most influential
Recent publications
Major themes5
- Neoplasms, Glandular and Epithelial2
- Thymoma2
- Thymus Neoplasms2
- Lung Neoplasms1
- Neuroendocrine Tumors1
Leading journals2
- ESMO open1
- Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer1
Leading researchers8
- Ahmad U1
- Appel S1
- Asamura H1
- Bille A1
- Boubia S1
- Brambilla C1
- Cangir AK1
- Carbone DP1
Affiliations (unnormalised)6
- and Thoracic Institute at Cleveland Clinic1
- Ankara University Faculty of Medicine1
- Asan Medical Center1
- Azienda Ospedaliero-Universitaria Pisana1
- Baggiovara Civil Hospital1
- Chaim Sheba Medical Center1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
A neoplasm originating from thymic tissue, usually benign, and frequently encapsulated. Although it is occasionally invasive, metastases are extremely rare. It consists of any type of thymic epithelial cell as well as lymphocytes that are usually abundant. Malignant lymphomas that involve the thymus, e.g., lymphosarcoma, Hodgkin's disease (previously termed granulomatous thymoma), should not be regarded as thymoma. (From Stedman, 25th ed)
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.